1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study

• DOI: 10.1016/j.annonc.2023.09.2722
• Publication Date: 2023-10-20T13:11:12Z
• Authors: C.J. Gratzke; M. Ozguroglu; A. Peer; M.A.N. Sendur; M. Retz; J.C.H. Goh; W.C. Loidl; G. Jayram; S-S. Byun; C. Kwak; M. Kwiatkowski; R. Manneh Kopp; J.C. Vazquez Limon; J.F. Escobar Penagos; U.F.F. De Giorgi; K.M.D. Trindade; C. Niu; Y. Liu; C.H. Poehlein; J.M. Piulats Rodr...
• Keywords: Enzalutamide; Clinical endpoint